Evaluation of Systemic Corticosteroids in Patients With an Acute Exacerbation of COPD and a Diagnosis of Pneumonia

被引:13
|
作者
Scholl, Tyler [1 ]
Kiser, Tyree H. [1 ]
Vondracek, Sheryl F. [1 ]
机构
[1] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, 12850 E Montview Blvd C238, Aurora, CO 80045 USA
关键词
hospitalized; length of stay; pneumonia; COPD; exacerbation; corticosteroids; COMMUNITY-ACQUIRED PNEUMONIA; OBSTRUCTIVE PULMONARY-DISEASE; PLACEBO-CONTROLLED TRIAL; INHALED CORTICOSTEROIDS; INFLAMMATORY RESPONSE; BLOOD EOSINOPHILS; CLINICAL-TRIAL; MANAGEMENT; OUTCOMES; EFFICACY;
D O I
10.15326/jcopdf.5.1.2017.0157
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Chronic obstructive pulmonary disease (COPD) and pneumonia are leading causes of morbidity and mortality and are frequently comorbid. Studies of systemic corticosteroids in pneumonia have shown conflicting outcomes, whereas studies in acute exacerbations of COPD (AECOPD) have shown significant benefits. No studies have evaluated systemic corticosteroids in patients with both an AECOPD and pneumonia. Purpose: To evaluate the use of systemic corticosteroids in patients with both an AECOPD and pneumonia. Patients and Methods: Patients with a diagnosis of both COPD or obstructive chronic bronchitis with exacerbation and pneumonia admitted to the University of Colorado Hospital between July 1, 2012 and May 20, 2016 were retrospectively evaluated. Patients who received systemic corticosteroids were compared to those that did not. The primary outcome was length of hospital stay (LOHS). Secondary outcomes were in-hospital treatment failure, a composite of intensive care unit (ICU) admission, ventilation, and escalation of steroid therapy, 30-day AECOPD or pneumonia readmission, and 30-day mortality. Results: A total of 138 patients were included-89 in the steroid group and 49 in the non-steroid group. No significant differences in baseline characteristic were noted. No difference was seen in mean LOHS (4.7 +/- 3.2 versus 4.2 +/- 2.1 days, p=0.27), in-hospital treatment failure (7% versus 4%, p=0.72), 30-day readmission or 30-day mortality between the steroid and non-steroid groups, respectively. There was a difference in mean LOHS for patients with severe pneumonia between the steroid and non-steroid groups (6.0 +/- 4.0 versus 4.3 +/- 1.8; p=0.03). Conclusions: This study suggests that systemic corticosteroids may not provide a clinical benefit to patients with an AECOPD and pneumonia.
引用
收藏
页码:57 / 65
页数:9
相关论文
共 50 条
  • [31] Mortality in Patients Admitted for Concurrent COPD Exacerbation and Pneumonia
    Sharafkhaneh, Amir
    Spiegelman, Andrew M.
    Main, Kevin
    Tavakoli-Tabasi, Shahriar
    Lan, Charlie
    Musher, Daniel
    COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2017, 14 (01) : 23 - 29
  • [32] Mortality in Patients Admitted for Concurrent COPD Exacerbation and Pneumonia
    Sharafkhaneh, Amir
    Tavakoli-Tabasi, Shahriar
    Musher, Daniel
    COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2017, 14 (04) : 462 - 462
  • [33] COPD or Not COPD? The Correlation Between Spirometry and a Discharge Diagnosis of an Acute COPD Exacerbation
    Mclaughlin, Cameron
    Skabelund, Andrew
    CHEST, 2016, 150 (04) : 841A - 841A
  • [34] A retrospective evaluation of inhaled corticosteroid use for COPD patients receiving systemic corticosteroids
    Steuber, Taylor
    PHARMACOTHERAPY, 2015, 35 (11): : E284 - E285
  • [35] Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD
    Snider, Julia Thornton
    Luna, Yesenia
    Wong, Ken S.
    Zhang, Jie
    Chen, Susan S.
    Gless, Patrick J.
    Goldman, Dana P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (12) : 1959 - 1967
  • [36] Serum Cytokine Evaluation of Acute Exacerbation in Patients with Idiopathic Interstitial Pneumonia
    Arai, T.
    Hirose, M.
    Kida, H.
    Ogata, Y.
    Matsuoka, H.
    Yamamoto, S.
    Sugimoto, C.
    Tachibana, K.
    Hatsuda, K.
    Akira, M.
    Inoue, Y.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [37] Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD
    Thornton, Julia
    Luna, Yesenia
    Wong, Ken
    Zhang, Jie
    Chen, Susan
    Goldman, Dana
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [38] Pneumonia and inhaled corticosteroids in COPD
    Jabbar, Avais
    THORAX, 2014, 69 (09) : 872 - 872
  • [39] The impact of mechanical ventilation on the systemic inflammatory response of patients with severe acute exacerbation of COPD
    Hillas, Georgios
    Katsaounou, Paraskevi
    Perlikos, Fotis
    Toumpanakis, Dimitris
    Litsiou, Eleni
    Nikolakopoulou, Sofia
    Sagris, Kostas
    Vassilakopoulos, Theodoros
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [40] Assessment of high-dose inhalational corticosteroids vs systemic corticosteroids in acute exacerbations of COPD in diabetic patients
    Magdy, A. S.
    Diab, Haytham S.
    EGYPTIAN JOURNAL OF BRONCHOLOGY, 2019, 13 (05) : 610 - 615